AscentGene — Stock, Pipeline & Market Cap

Is this your company? Claim your profile to update info and connect with investors.

Private Company

Funding information not available

Overview

Founded in 2015 and based in San Diego, AscentGene operates as a service provider in the genetics and genomics sector, focusing on cell line engineering and protein services. The company caters to academic, biotech, and pharmaceutical clients, utilizing a team with deep expertise in molecular biology and biochemistry. While historically involved in early-stage research programs like VLP-based vaccines, its core business appears to be fee-for-service, positioning it as a critical enabler for broader therapeutic and diagnostic development.

Genetics & GenomicsDiagnostics

Technology Platform

Cell line engineering using highly expressive vectors and innovative selection methods; complete protein service pipeline from subcloning to purification; production of active nuclear and cytoplasmic cellular extracts.

Opportunities

The growing outsourcing trend in biopharma R&D and the sustained demand for biologics create a strong market for specialized cell line and protein services.

The company's expertise in transcription factors and active extracts positions it well in the functional genomics and proteomics research markets.

Risk Factors

Faces intense competition from larger, well-capitalized CROs and reagent suppliers.

Revenue is tied to client R&D budgets, which can be cyclical.

Maintaining technological differentiation and service quality with limited scale is an ongoing challenge.

Competitive Landscape

AscentGene competes in the fragmented life sciences services and tools market against global giants like Thermo Fisher Scientific and Lonza, as well as numerous specialized CROs. Its differentiation hinges on deep expertise in molecular biology, speed in cell line generation, and a focus on active functional cellular components.

More companies in Biologics / Biosimilars →More companies in United States →